Advice
following a full submission:
Pegvisomant (Somavert) is not recommended for use within NHS Scotland for the treatment of patients with acromegaly who have had an inadequate esponse to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalise IGF-1 concentrations or was not tolerated. visomant reduces IGF-1 levels significantly, as well as improving some of the clinical manifestations of acromegaly. Although it is acknowledged that this is an orphan drug the cost-effectiveness is Poor.
The licence holder has indicated their decision to resubmit.
Download detailed advice48KB (PDF)
Medicine details
- Medicine name:
- pegvisomant (Somavert)
- SMC ID:
- 158/05
- Indication:
- Acromegaly
- Pharmaceutical company
- Pfizer Ltd
- BNF chapter
- Endocrine system
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 09 May 2005